KR100562274B1 - 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 - Google Patents
수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 Download PDFInfo
- Publication number
- KR100562274B1 KR100562274B1 KR1020040037943A KR20040037943A KR100562274B1 KR 100562274 B1 KR100562274 B1 KR 100562274B1 KR 1020040037943 A KR1020040037943 A KR 1020040037943A KR 20040037943 A KR20040037943 A KR 20040037943A KR 100562274 B1 KR100562274 B1 KR 100562274B1
- Authority
- KR
- South Korea
- Prior art keywords
- dendritic cells
- cells
- peripheral blood
- leukocytes
- dendritic
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
말초혈액으로부터 조혈모세포를 포함하는 백혈구를 분리하는 데 있어서는 채혈 과정 중 조혈 기능을 촉진하기 위해서 필요에 따라서는 종양 환자에게 5 ㎍/㎏/day의 용량으로 G-CSF를 3일 동안 피하주사로 투여한 다음 채혈할 수 있다. 또한 백혈구를 수지상세포로 유도분화시킨 후 인식(감작)시킬 표적항원을 채취하기 위하여 환자의 말초혈에서 전혈 20ml을 채혈하여서 혈청을 냉동보관한다.
치료 전 | 치료 후 | |
CD3(%) | 43.5 | 49.0 |
CD4(%) | 28.2 | 27.7 |
CD8(%) | 16.2 | 22.0 |
CD4 : CD8 | 1.74 : 1 | 1.26:1 |
CD56(%) | 14.8 | 12.4 |
NK 세포의 활성(%) | 15.7 | 28.9 |
Claims (8)
- (정정)말초혈액으로부터 분리한 전구세포를, 사이토카인 칵테일을 사용하여 체외에서(in vitro) 수지상 세포로 분화 유도하여 수지상 세포를 제조하는 방법에 있어서,상기 전구세포는 조혈모세포를 포함하는 백혈구이며, 사이토카인 칵테일은 섬유 근육통 증후군 관련 티로신 키나제 3-리간드(Flt3-ligand), 과립구-대식세포 콜로니 자극 인자(GM-CSF), 인터류킨-4(IL-4) 및 종양 괴사 인자(TNF-α)를 포함하는 사이토카인 칵테일(cytokines cocktail)인 것을 특징으로 하는 수지상 세포(dendritic cells)의 제조 방법.
- (삭제)
- (삭제)
- (삭제)
- (정정)제1항에 있어서, 사이토카인 칵테일은 섬유 근육통 증후군 관련 티로신 키나제 3-리간드(Flt3-ligand) 25-50 ng/ml, 과립구-대식세포 콜로니 자극 인자(GM-CSF) 50 ng/ml 내지 1 mg/ml, 인터류킨-4(IL-4) 25-50 ng/ml 및 종양 괴사 인자(TNF-α) 10-20 ng/ml를 포함하는 것을 특징으로 하는 수지상 세포의 제조 방법.
- (정정)제1항 또는 제5항에 따른 방법에 의해 제조되며, 그 표면에 CD1a, CD83 및 CD86 항원을 포함하는 수지상 세포.
- (정정)제6항의 수지상 세포; 및약학적 허용 담체, 부형제 또는 이들의 혼합물을 포함하는 악성 종양의 치료용 또는 예방용 약학 조성물.
- (정정)제7항에 있어서, 상기 수지상 세포는 80ml의 생리식염수에 현탁시 그 양이 환자의 체중 1 kg당 1x106 - 3x106개 정도 되도록 포함되는 것을 특징으로 하는 악성 종양의 치료용 또는 예방용 약학 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040037943A KR100562274B1 (ko) | 2004-05-27 | 2004-05-27 | 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040037943A KR100562274B1 (ko) | 2004-05-27 | 2004-05-27 | 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050113344A KR20050113344A (ko) | 2005-12-02 |
KR100562274B1 true KR100562274B1 (ko) | 2006-03-22 |
Family
ID=37287970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040037943A KR100562274B1 (ko) | 2004-05-27 | 2004-05-27 | 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100562274B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100675761B1 (ko) * | 2005-09-01 | 2007-01-30 | 주식회사 바이넥스 | 1,2-디옥타노일-sn-글리세롤3-포스페이트를 이용한 급성골수성 백혈병 세포의 수지상 세포로의 전이분화 유도 방법 |
KR100914520B1 (ko) * | 2007-08-16 | 2009-09-02 | 동아대학교 산학협력단 | 3―Br―Fas 또는 10―Br―Fas를 유효성분으로함유하는 수지상 세포의 성숙화 유도용 조성물 |
-
2004
- 2004-05-27 KR KR1020040037943A patent/KR100562274B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20050113344A (ko) | 2005-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2348418C2 (ru) | Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей | |
KR20000049096A (ko) | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 | |
US20030124091A1 (en) | Endothelial cell derived hematopoietic growth factor | |
Liu et al. | Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects | |
JP2024019229A (ja) | 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 | |
EP2878666B1 (en) | Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes | |
EP0690125B1 (en) | Process for induction culture of cytotoxic T lymphocytes having killing activity against tumor cells | |
CN111117964B (zh) | 一种肿瘤来源外泌体及其制备方法和用途 | |
KR100562274B1 (ko) | 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물 | |
TW200404002A (en) | Treatment method achieved by using the lymphocytes derived from HLA matching donor-originating activated lymphocytes, formula having the lymphocytes as a main constituent thereof; method and preparation kit for manufacturing the formula | |
WO2011060205A1 (en) | Methods, compositions, and assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease | |
BG107482A (bg) | Лекарствено средство за имунотерапия на злокачествени тумори | |
Zheng et al. | Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery | |
KR20180022949A (ko) | 향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포 | |
CN117402218B (zh) | 一种Survivin阳性肿瘤的个体化树突状细胞疫苗及其制备方法 | |
KR100429140B1 (ko) | 인간 조혈 모세포로부터 분화되는 림프구성 수상돌기 세포및 그의 생산 방법 | |
AU2018260971B2 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
Svedersky et al. | Immune suppression by cultured lymphocyte supernates of tumor‐bearing hosts | |
CN116370496A (zh) | 胀果甘草多糖在制备治疗和/或预防肝癌的药物中的应用 | |
CN114657124A (zh) | 一种对肿瘤细胞具有高杀伤能力的复合型免疫细胞制备方法 | |
Shabeeb et al. | Immunophenotypic Study of the Cord Blood CD34+ Progenitor Stem Cells-Derived Dendritic Cells | |
US20080220025A1 (en) | Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells | |
CZ29538U1 (cs) | Sada pro přípravu protinádorové vakcíny, protinádorová vakcína včetně posílení účinku | |
CZ22766U1 (cs) | Sada pro přípravu protínádorové vakcíny a protinádorová vakcína | |
AU2013234394A1 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130313 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140313 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160226 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170220 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180208 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200225 Year of fee payment: 15 |